1.Gordts S, Grimbizis G, Campo R. Symptoms and classification of uterine adenomyosis, including the place of hysteroscopy in diagnosis. Fertil Steril 2018;109:380e388.e1.

2.Naftalin J, Hoo W, Pateman K, et al. How common is adenomyosis? A prospective study of prevalence using transvaginal ultrasound in a gynaecology clinic. Hum Reprod 2012;27:3432e9.

3.Pinzauti S, Lazzeri L, Tosti C, et al. Transvaginal sonographic features of diffuse adenomyosis in 18e30-year-old nulligravid women without endometriosis: association with symptoms. Ultrasound Obstet Gynecol 2015;46:730e6.

4.Puente JM, Fabris A, Patel J, et al. Adenomyosis in infertile women: prevalence and the role of 3D ultrasound as a marker of severity of the disease. Reprod Biol Endocrinol 2016;14:60.

5.Naftalin J, Hoo W, Nunes N, et al. Association between ultrasound features of adenomyosis and severity of menstrual pain. Ultrasound Obstet Gynecol 2016;47:779e83.

6.Naftalin J, Hoo W, Pateman K, et al. Is adenomyosis associated with menorrhagia? Hum Reprod 2014;29:473e9.

7.Nirgianakis K, Kalaitzopoulos DR, Schwartz ASK, et al. Fertility, pregnancy and neonatal outcomes of patients with adenomyosis: a systematic review and meta-analysis. Reprod Biomed Online 2021;42:185e206.

8.Munro MG. Classification and reporting systems for adenomyosis. J Minim Invasive Gynecol 2020;27:296e308.

9.Van den Bosch T, de Bruijn AM, de Leeuw RA, et al. Sonographic classification and reporting system for diagnosing adenomyosis. Ultrasound Obstet Gynecol 2019;53:576e82.

10.Tellum T, Nygaard S, Skovholt EK, et al. Development of a clinical prediction model for diagnosing adenomyosis. Fertil Steril 2018;110:957e964.e3.

11.Bazot M, Daraï E. Role of transvaginal sonography and magnetic resonance imaging in the diagnosis of uterine adenomyosis. Fertil Steril 2018;109:389e97.

12.Maxim M, Dason ES, Chan C, et al. Current diagnosis and management of adenomyosis in Canada: a survey of Canadian gynaecologists. J Endometr Pelvic Pain Disord 2022;14:98e105.

13.Zannoni L, Ambrosio M, Raimondo D, et al. Question mark sign and transvaginal ultrasound uterine tenderness for the diagnosis of adenomyosis: a prospective validation. J Ultrasound Med 2020;39:1405e12.

14.Loring M, Chen TY, Isaacson KB. A systematic review of adenomyosis: it is time to reassess what we thought we knew about the disease. J Minim Invasive Gynecol 2021;28:644e55.

15.Olgan S, Dirican EK, Ozsipahi AC, et al. Uterine involvement by endometriosis: sonographic features from elusive findings to apparent adenomyosis. Eur J Obstet Gynecol Reprod Biol 2021;262:93e8.

16.Andres MP, Borrelli GM, Ribeiro J, et al. Transvaginal ultrasound for the diagnosis of adenomyosis: systematic review and meta-analysis. J Minim Invasive Gynecol 2018;25:257e64.

17.Marques ALS, Andres MP, Mattos LA, et al. Association of 2D and 3D transvaginal ultrasound findings with adenomyosis in symptomatic women of reproductive age: a prospective study. Clinics (Sao Paulo) 2021;76:e2981.

18.Champaneria R, Abedin P, Daniels J, et al. Ultrasound scan and magnetic resonance imaging for the diagnosis of adenomyosis: systematic review comparing test accuracy. Acta Obstet Gynecol Scand 2010;89:1374e84.

19.Rees CO, Nederend J, Mischi M, et al. Objective measures of adenomyosis on MRI and their diagnostic accuracy-a systematic review & meta-analysis. Acta Obstet Gynecol Scand 2021;100:1377e91.

20.Takeuchi M, Matsuzaki K. Adenomyosis: usual and unusual imaging manifestations, pitfalls, and problem-solving MR imaging techniques. RadioGraphics 2011;31:99e115.

21.Movilla P, Morris S, Isaacson K. A systematic review of tissue sampling techniques for the diagnosis of adenomyosis. J Minim Invasive Gynecol 2020;27:344e51.

22.Jeng CJ, Huang SH, Shen J, et al. Laparoscopy-guided myometrial biopsy in the definite diagnosis of diffuse adenomyosis. Hum Reprod 2007;22:2016e9.

23.Singh S, Best C, Dunn S, et al. No. 292-abnormal uterine bleeding in premenopausal women. J Obstet Gynaecol Can 2018;40:e391e415.

24.Ozdegirmenci O, Kayikcioglu F, Akgul MA, et al. Comparison of levonorgestrel intrauterine system versus hysterectomy on efficacy and quality of life in patients with adenomyosis. Fertil Steril 2011;95:497e502.

25.Shaaban OM, Ali MK, Sabra AMA, et al. Levonorgestrel-releasing intrauterine system versus a low-dose combined oral contraceptive for treatment of adenomyotic uteri: a randomized clinical trial. Contraception 2015;92:301e7.

26.Abbas AM, Samy A, Atwa K, et al. The role of levonorgestrel intra-uterine system in the management of adenomyosis: a systematic review and meta-analysis of prospective studies. Acta Obstet Gynecol Scand 2020;99:571e81.

27.Song SY, Lee SY, Kim HY, et al. Long-term efficacy and feasibility of levonorgestrel-releasing intrauterine device use in patients with adenomyosis. Med (Baltim) 2020;99:e20421.

28.Li L, Leng J, Jia S, et al. Treatment of symptomatic adenomyosis with the levonorgestrel-releasing intrauterine system. Int J Gynaecol Obstet 2019;146:357e63.

29.Chen S, Wang J, Sun W, et al. Efficacy of the levonorgestrel-releasing intrauterine device is associated with different subtypes of adenomyosis: a retrospective study. Ann Transl Med 2020;8:1356.

30.Osuga Y, Watanabe M, Hagino A. A randomized, double-blind, multicenter, placebo-controlled study of dienogest in the treatment of painful symptoms in patients with adenomyosis in Japan. Jpn Pharmacol Ther 2017;45:907e20.

31.Hassanin AI, Youssef AAAM, Yousef AM, et al. Comparison of dienogest versus combined oral contraceptive pills in the treatment of women with adenomyosis: a randomized clinical trial. Int J Gynaecol Obstet 2021;154:263e9.

32.Ono N, Asano R, Nagai K, et al. Evaluating the safety of dienogest in women with adenomyosis: a retrospective analysis. J Obstet Gynaecol Res 2021;47:1433e40.

33.Neriishi K, Hirata T, Fukuda S, et al. Long-term dienogest administration in patients with symptomatic adenomyosis. J Obstet Gynaecol Res 2018;44:1439e44.

34.Muneyyirci-Delale O, Chandrareddy A, Mankame S, et al. Norethindrone acetate in the medical management of adenomyosis. Pharmaceuticals (Basel) 2012;5:1120e7.

35.Vannuccini S, Luisi S, Tosti C, et al. Role of medical therapy in the management of uterine adenomyosis. Fertil Steril 2018;109:398e405.

36.Matsushima T, Akira S, Fukami T, et al. Efficacy of hormonal therapies for decreasing uterine volume in patients with adenomyosis. Gynecol Minim Invasive Ther 2018;7:119e23.

37.Andreeva E, Absatarova Y. Triptorelin for the treatment of adenomyosis: a multicenter observational study of 465 women in Russia. Int J Gynaecol Obstet 2020;151:347e54.

38.Matsushima T, Akira S, Yoneyama K, et al. Recurrence of uterine adenomyosis after administration of gonadotropin-releasing hormone agonist and the efficacy of dienogest. Gynecol Endocrinol 2020;36:521e4.

39.Vannuccini S, Petraglia F. Recent advances in understanding and managing adenomyosis. F1000Res 2019;8:Faculty Rev-283.

40.Akira S, Mine K, Kuwabara Y, et al. Efficacy of long-term, low-dose gonadotropin-releasing hormone agonist therapy (draw-back therapy) for adenomyosis. Med Sci Monit 2009;15:CR1e4.

41.Donnez O, Donnez J. Gonadotropin-releasing hormone antagonist (linzagolix): a new therapy for uterine adenomyosis. Fertil Steril 2020;114:640e5.

42.Tosti C, Vannuccini S, Troìa L, et al. Long-term vaginal danazol treatment in fertile age women with adenomyosis. J Endometriosis Pelvic Pain Disord 2017;9:39e43.

43.Capmas P, Brun JL, Legendre G, et al. Ulipristal acetate use in adenomyosis: a randomized controlled trial. J Gynecol Obstet Hum Reprod 2021;50:101978.

44.Badawy AM, Elnashar AM, Mosbah AA. Aromatase inhibitors or gonadotropin-releasing hormone agonists for the management of uterine adenomyosis: a randomized controlled trial. Acta Obstet Gynecol Scand 2012;91:489e95.

45.Chen J, Porter AE, Kho KA. Current and future surgical and interventional management options for adenomyosis. Semin Reprod Med 2020;38:157e67.

46.de Bruijn AM, Smink M, Lohle PNM, et al. Uterine artery embolization for the treatment of adenomyosis: a systematic review and meta-analysis. J Vasc Interv Radiol 2017;28:1629e1642.e1.

47.de Bruijn AM, Lohle PN, Huirne JA, et al. Uterine artery embolization versus hysterectomy in the treatment of symptomatic adenomyosis: protocol for the randomized QUESTA trial. JMIR Res Protoc 2018;7:e47.

48.Zhou J, He L, Liu P, et al. Outcomes in adenomyosis treated with uterine artery embolization are associated with lesion vascularity: a long-term follow-up study of 252 cases. PLoS One 2016;11:e0165610.

49.Smeets AJ, Nijenhuis RJ, Boekkooi PF, et al. Long-term follow-up of uterine artery embolization for symptomatic adenomyosis. Cardiovasc Intervent Radiol 2012;35:815e9.

50.Philip CA, Le Mitouard M, Maillet L, et al. Evaluation of NovaSure® global endometrial ablation in symptomatic adenomyosis: a longitudinal study with a 36 month follow-up. Eur J Obstet Gynecol Reprod Biol 2018;227:46e51.

51.Lou J, Huang X, Zhang L, et al. [The second generation endometrial ablation (NovaSure) improves efficacy of levonorgestrel-releasing intrauterine system in management of adenomyosis]. Zhejiang Da Xue Xue Bao Yi Xue Ban 2019;48:136e41.

52.Osada H. Uterine adenomyosis and adenomyoma: the surgical approach. Fertil Steril 2018;109:406e17.

53.Thurston J, Murji A, Scattolon S, et al. No. 377-hysterectomy for benign gynaecologic indications. J Obstet Gynaecol Can 2019;41:543e57.

54.Squillace ALA, Simonian DS, Allegro MC, et al. Adenomyosis and in vitro fertilization impacts - A literature review. JBRA Assist Reprod 2021;25:303e9.

55.Younes G, Tulandi T. Effects of adenomyosis on in vitro fertilization treatment outcomes: a meta-analysis. Fertil Steril 2017;108:483e490.e3.

56.Liang Z, Yin M, Ma M, et al. Effect of pretreatment with a levonorgestrelreleasing intrauterine system on IVF and vitrified-warmed embryo transfer outcomes in women with adenomyosis. Reprod Biomed Online 2019;39:111e8.

57.Park CW, Choi MH, Yang KM, et al. Pregnancy rate in women with adenomyosis undergoing fresh or frozen embryo transfer cycles following gonadotropin-releasing hormone agonist treatment. Clin Exp Reprod Med 2016;43:169e73.

58.Lan J, Wu Y, Wu Z, et al. Ultra-long GnRH agonist protocol during IVF/ICSI improves pregnancy outcomes in women with adenomyosis: a retrospective cohort study. Front Endocrinol 2021;12:609771.

59.Niu Z, Chen Q, Sun Y, et al. Long-term pituitary downregulation before frozen embryo transfer could improve pregnancy outcomes in women with adenomyosis. Gynecol Endocrinol 2013;29:1026e30.

60.Stanekova V, Woodman RJ, Tremellen K. The rate of euploid miscarriage is increased in the setting of adenomyosis. Hum Reprod Open 2018;2018:hoy011.

61.Mavrelos D, Holland TK, O’Donovan O, et al. The impact of adenomyosis on the outcome of IVF-embryo transfer. Reprod Biomed Online 2017;35:549e54.

62.Sharma S, Bathwal S, Agarwal N, et al. Does presence of adenomyosis affect reproductive outcome in IVF cycles? A retrospective analysis of 973 patients. Reprod Biomed Online 2019;38:13e21.

63.Higgins C, Fernandes H, Da Silva Costa F, et al. The impact of adenomyosis on IVF outcomes: a prospective cohort study. Hum Reprod Open 2021;2021:hoab015.

64.Dason ES, Maxim M, Hartman A, et al. Pregnancy outcomes with donor oocyte embryos in patients diagnosed with adenomyosis using the Morphological Uterus Sonographic Assessment (MUSA) criteria. Fertil Steril 2023;119:484e9.